Sanara MedTech Inc. (SMTI)
SMTINASDAQ-CMIndustrial Specialties
$32.35
-0.1100 (-0.34%) today
Closed, Nov 13, 4:00 PM ET
- Market cap
- $297.06m
- P/E
- 129.4
- EPS, last 4 quarters
- $0.2500
- Dividend yield
- –
- Day range
- –
- 52-week range
- $16.05 to $35.52
- Average volume
- –
- Previous close
- $32.46
Analysts
1 coveringHold0 buy, 1 hold, 0 sell
Targets a year out average $35.00, +8.2% from here
Earnings
next estimate $0.1200Next report
Dec 2025
-63.6%
Mar 2026
+200.0%
Jun 2026
+150.0%
Sep 2026
+100.0%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $27.55m | $27.80m | $28.14m | $28.43m |
| Gross profit | $25.67m | $25.88m | $26.16m | $26.32m |
| Operating income | $1.05m | $2.65m | $1.78m | $736.0k |
| Net income | -$1.61m | $459.0k | -$453.0k | -$1.41m |
Last four quarters: revenue $111.91m, margin -2.7%, free cash flow –
News
8 latest- Sanara MedTech Inc. (SMTI) Surpasses Q3 Earnings EstimatesZacks · 3 days ago
- Village Farms (VFF) Tops Q3 Earnings and Revenue EstimatesZacks · 6 days ago
- Cresco Labs Inc. (CRLBF) Reports Q3 Loss, Misses Revenue EstimatesZacks · Nov 6, 2026
- Apyx Medical (APYX) Reports Q3 Loss, Tops Revenue EstimatesZacks · Nov 5, 2026
- Sanara MedTech Inc. Sells Tissue Health Plus, LLC Assets for approximately $2,000,000Fintel · Oct 30, 2026
- Sanara MedTech Inc. (SMTI) Tops Q2 Earnings EstimatesZacks · Aug 11, 2026
- biote Corp. (BTMD) Reports Break-Even Earnings for Q2Zacks · Aug 5, 2026
- MiMedx To Acquire Sanara MedTech In $350 Million Deal; Stock Up RTTNews · Jul 30, 2026
The company
Sanara MedTech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. The Company develops, markets and distributes surgical products for use by physicians and clinicians in hospitals. Each of the Company's products and technologies is designed to achieve the goal of providing better clinical outcomes at a lower overall cost for healthcare systems. Sanara's products are primarily sold in the North American surgical tissue repair market. Sanara markets and distributes CellerateRX Surgical Powder, BIASURGE Advanced Surgical Solution, FORTIFY TRG Tissue Repair Graft and FORTIFY FLOWABLE Extracellular Matrix, as well as a portfolio of advanced biologic products including: ACTIGENTM Verified Inductive Bone Matrix, ALLOCYTE Plus Advanced Viable Bone Matrix, BiFORM Bioactive Moldable Matrix and TEXAGEN Amniotic Membrane Allograft to the surgical market.
- Sector
- Health Care
- Industry
- Industrial Specialties
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- sanaramedtech.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.